GlassScriptPhysician profile
Raymond G Maceren
NPI 1891706503
$16,027.26
in general payments reported to CMS, 2019-2025
52 companies · $1,728 in 2025
The $1,728 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,047 · 2020: $2,678 · 2021: $3,353 · 2022: $2,318 · 2023: $1,877 · 2024: $2,026 · 2025: $1,728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,630.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,806.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,798.63 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,592.55 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,290.44 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $1,046.64 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $889.23 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Allergan, INC. | $715.06 | 2019-2020 | |
| Amgen INC. | $700.53 | 2019-2025 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $695.50 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $473.89 | 2019-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $430.50 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Pfizer INC. | $417.15 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $412.39 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $398.39 | 2022-2025 | Rexulti |
| Amarin Pharma, INC. | $381.77 | 2019-2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Maceren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.